CLIP2::MET fusion identifies a molecularly distinct glioneuronal tumor Authors: Jawad Fares, Jared T. Ahrendsen, Harrshavasan T. Congivaram, Lucas Santana-Santos, Daniel Oyon, Karan Dixit, Mark W. Youngblood, James P. Chandler Published: 2026 ABSTRACT Glioneuronal tumors are rare central nervous system (CNS) neoplasms with heterogeneous clinical, histological, and molecular features. Diagnosis and classification are often challenging due to overlapping morphology and limited defining alterations. Here, we present a 19-year-old female with a right frontal lobe glioneuronal tumor, initially suspected to be a low-grade glioma. Histology revealed mixed glial and neuronal elements with low proliferative activity. Standard molecular testing was negative for IDH1/IDH2 and BRAF mutations. DNA methylation profiling did not match to any known CNS class but clustered most closely with low-grade glioma/ganglioglioma. Next-generation RNA sequencing identified a CLIP2::MET fusion as the sole pathogenic alteration. MET fusions are actionable oncogenic drivers across several cancers, and their detection has therapeutic relevance with approved inhibitors. This case expands the spectrum of MET-driven CNS tumors and suggests that CLIP2::MET fusion may represent a distinct molecular subset of glioneuronal tumors relevant to precision oncology. Introduction Glioneuronal tumors are uncommon central nervous system (CNS) neoplasms characterized by mixed glial and neuronal differentiation. Their clinical and histological spectrum is wide, and diagnosis can be challenging due to morphologic overlap with other low-grade gliomas and neuronal–glial tumors. Advances in molecular profiling have improved the classification of these tumors, yet their full spectrum of molecular alterations remains incompletely defined [1]. Receptor tyrosine kinase fusions, including those involving ALK, ROS1, NTRK, and MET, have emerged as recurrent oncogenic drivers in pediatric and adult gliomas [2, 3]. MET encodes the hepatocyte growth factor receptor (HGFR), a receptor tyrosine kinase that regulates cell proliferation, survival, and motility. Aberrant activation of MET through amplification, mutation, or fusion promotes oncogenic signaling via MAPK and PI3K/AKT pathways, and has been implicated in multiple cancer types [4, 5]. MET alterations, in particular, are implicated in tumor proliferation, invasion, and treatment resistance, and targeted inhibitors are now approved for use in non-CNS cancers [6]. Within the CNS, MET fusions remain rare but are increasingly recognized as biologically relevant events. CLIP2::MET fusions have been described in only a handful of gliomas, spanning both high-grade pediatric cases and rare glioneuronal tumors [7–9], suggesting a role in tumorigenesis across a spectrum of disease. Recent studies have further delineated molecularly defined subsets of glioneuronal tumors driven by receptor tyrosine kinase fusions, highlighting the heterogeneity of these neoplasms and the potential for fusion-defined classification [10, 11]. Despite their rarity, identifying MET fusions has direct therapeutic implications. The availability of clinically approved MET inhibitors highlights the importance of recognizing such fusions in diagnostically ambiguous CNS tumors [6]. However, the limited number of reported cases underscores the need for continued documentation and integration of these findings into molecular classification frameworks. Here, we report a 19-year-old female with a glioneuronal tumor harboring a CLIP2::MET fusion as the sole pathogenic alteration. The tumor did not match to any known CNS methylation class, clustering instead with low-grade glioma/ganglioglioma, raising the possibility that CLIP2::MET–driven glioneuronal tumors may represent a novel molecular subset. This case expands the spectrum of MET-driven CNS tumors and illustrates the value of comprehensive genomic profiling in informing diagnosis and uncovering actionable alterations relevant to precision oncology. Clinical summary The patient was a 19-year-old female who presented with a first-time seizure. MRI demonstrated a non-enhancing, cortically based lesion in the right frontal lobe, measuring 25 × 20 × 15 mm. The lesion was hyperintense on T2-weighted and FLAIR sequences, without associated restricted diffusion, significant mass effect, or surrounding edema, and was radiographically consistent with a low-grade glioneuronal neoplasm (Fig. 1a-d). She underwent frameless navigated craniotomy with gross total resection (Fig. 1e, f). Postoperatively, she developed left upper extremity weakness, which improved with rehabilitation. At six months of follow-up, the patient remained clinically stable without radiographic evidence of recurrence. Fig. 1MRI of a right frontal glioneuronal tumor. a Pre-operative axial post-contrast T1-weighted and b coronal post-contrast T1-weighted sequences demonstrate a largely non-enhancing right frontal lesion (yellow arrows). c Pre-operative axial T2-weighted and d coronal FLAIR sequences show a hyperintense cortical and subcortical lesion with mild mass effect (yellow arrows). The imaging features were consistent with a low-grade glioma. e Post-operative axial post-contrast T1-weighted and f coronal post-contrast T1-weighted sequences demonstrating gross total resection of the lesion MRI of a right frontal glioneuronal tumor. a Pre-operative axial post-contrast T1-weighted and b coronal post-contrast T1-weighted sequences demonstrate a largely non-enhancing right frontal lesion (yellow arrows). c Pre-operative axial T2-weighted and d coronal FLAIR sequences show a hyperintense cortical and subcortical lesion with mild mass effect (yellow arrows). The imaging features were consistent with a low-grade glioma. e Post-operative axial post-contrast T1-weighted and f coronal post-contrast T1-weighted sequences demonstrating gross total resection of the lesion Pathological findings Histological examination showed a mildly hypercellular glioneuronal tumor composed of cells with angulated nuclei and fibrillary cytoplasm, interspersed with scattered dysmorphic neurons. No necrosis, microvascular proliferation, or mitotic activity was observed. Immunohistochemistry revealed strong expression of GFAP and Olig2 in tumor cells, with NeuN and synaptophysin highlighting scattered neuronal elements. S100 was diffusely positive. The Ki-67 proliferation index was low, averaging 1–2% with focal areas up to 5% (Fig. 2a-f). Fig. 2Histopathologic and immunohistochemical features of the glioneuronal tumor. a Hematoxylin and eosin (H&E) sections demonstrate a low-grade fibrillary glioneuronal tumor composed of atypical, hyperchromatic glial cells with occasional enlarged ganglioid cells, including binucleate forms, and scattered microcalcifications. b Tumor cells show diffuse immunoreactivity for GFAP. c NeuN highlights entrapped neuronal elements. d Neurofilament immunostaining highlights axons coursing through the tumor. e A subset of tumor cells are positive for Olig2. f Ki-67 immunostaining shows a low proliferative index. Scale bars, 100 μm Histopathologic and immunohistochemical features of the glioneuronal tumor. a Hematoxylin and eosin (H&E) sections demonstrate a low-grade fibrillary glioneuronal tumor composed of atypical, hyperchromatic glial cells with occasional enlarged ganglioid cells, including binucleate forms, and scattered microcalcifications. b Tumor cells show diffuse immunoreactivity for GFAP. c NeuN highlights entrapped neuronal elements. d Neurofilament immunostaining highlights axons coursing through the tumor. e A subset of tumor cells are positive for Olig2. f Ki-67 immunostaining shows a low proliferative index. Scale bars, 100 μm Targeted next-generation sequencing confirmed that the tumor was wildtype for IDH1/IDH2 and negative for BRAF V600E. Microsatellite stability testing was normal, and chromosomal microarray analysis revealed no significant copy number changes. RNA sequencing identified a CLIP2::MET fusion with breakpoints at chr7:73,795,193 (CLIP2) and chr7:116,414,935 (MET). The fusion joins the 5′ portion of CLIP2 to MET exon 14, resulting in an in-frame transcript predicted to retain the MET tyrosine kinase domain (encoded by exons 15–21). The breakpoint in CLIP2 lies within the CAP-Gly domain, suggesting preservation of key structural elements in the fusion protein (Fig. 3a, b). The fusion was identified through a clinically validated RNA sequencing platform and confirmed per institutional molecular diagnostic workflows. Fig. 3Genomic characterization of the CLIP2::MET fusion. a Copy number analysis demonstrates a segmental interstitial deletion at chromosome 7q31.2 (red arrow), resulting in juxtaposition of CLIP2 and MET. RNA sequencing confirmed the presence of a CLIP2::MET fusion transcript. b Schematic representation of the fusion, with breakpoints at chr7:73,795,193 (CLIP2) and chr7:116,414,935 (MET). The fusion joins the 5′ portion of CLIP2, with the breakpoint located within the CAP-Gly domain, to MET exon 14, resulting in an in-frame transcript predicted to retain the MET tyrosine kinase domain (exons 15–21). The predicted chimeric protein preserves key functional domains from both partners Genomic characterization of the CLIP2::MET fusion. a Copy number analysis demonstrates a segmental interstitial deletion at chromosome 7q31.2 (red arrow), resulting in juxtaposition of CLIP2 and MET. RNA sequencing confirmed the presence of a CLIP2::MET fusion transcript. b Schematic representation of the fusion, with breakpoints at chr7:73,795,193 (CLIP2) and chr7:116,414,935 (MET). The fusion joins the 5′ portion of CLIP2, with the breakpoint located within the CAP-Gly domain, to MET exon 14, resulting in an in-frame transcript predicted to retain the MET tyrosine kinase domain (exons 15–21). The predicted chimeric protein preserves key functional domains from both partners DNA methylation profiling was performed on formalin-fixed, paraffin-embedded (FFPE) tumor tissue using the Illumina Infinium MethylationEPIC (850k) array. Data were analyzed using the DKFZ CNS tumor classifier (v12.8), the NIH/NCI classifier (v2.0), and institutional NMH CNS and tumor-of-unknown-origin (TUO) classifiers [12, 13]. A calibrated confidence score ≥ 0.9 was considered a definitive class match; scores < 0.9 were considered non-classifying. Dimensionality reduction (t-SNE) was performed using classifier platform defaults, and tumor clustering was assessed relative to reference cohorts. The tumor did not match a defined methylation class across classifiers but consistently localized near the low-grade glioma/ganglioglioma spectrum (Fig. 4). Fig. 4DNA methylation profiling and t-SNE clustering of the tumor. Two-dimensional t-SNE embedding of DNA methylation data demonstrates the position of the tumor (highlighted as “Case”) relative to reference central nervous system tumor methylation classes. The sample does not align with a definitive methylation class but localizes in proximity to the low-grade glioma/ganglioglioma spectrum and related glioneuronal tumor clusters. Embedding was performed using classifier-specific reference datasets and default parameters DNA methylation profiling and t-SNE clustering of the tumor. Two-dimensional t-SNE embedding of DNA methylation data demonstrates the position of the tumor (highlighted as “Case”) relative to reference central nervous system tumor methylation classes. The sample does not align with a definitive methylation class but localizes in proximity to the low-grade glioma/ganglioglioma spectrum and related glioneuronal tumor clusters. Embedding was performed using classifier-specific reference datasets and default parameters The Northwestern CNS tumor classifier (NMH CNS) classifier yielded no definitive match [12], although t-SNE clustering placed the tumor nearest to the “low-grade glioma, ganglioglioma” reference cohort. The Northwestern tumor of unknown origin (NMH TUO) classifier identified the tumor only as “Brain,” without further specificity [13]. Using the DKFZ v12.8 classifier, the tumor generated no definitive match but showed partial similarity to “low-grade glioma/glioneuronal tumor” (score 0.70) and “ganglioglioma” (score 0.46), with UMAP positioning near ganglioglioma and extraventricular neurocytoma. Finally, the NIH/NCI v2.0 classifier assigned the tumor to the “low-grade glioma/glioneuronal tumor” family (0.99) with a suggested class match to ganglioglioma (0.68), and its UMAP clustered in close proximity to dysembryoplastic neuroepithelial tumor and myxoid ganglioglioma. These results indicate that the tumor does not align with a known CNS methylation class but consistently clusters with the low-grade glioneuronal/ganglioglioma family. MGMT promoter methylation was not detected. Detailed preprocessing, normalization, and classifier development for the NMH CNS and NMH TUO platforms have been previously described and used [12–14]. Discussion Our presented case highlights a rare CLIP2::MET fusion in a glioneuronal tumor, contributing to the emerging literature on MET-driven neoplasms. MET fusions have been primarily recognized in aggressive pediatric high-grade gliomas and glioblastomas, where they activate MAPK and PI3K signaling pathways to promote tumor proliferation and progression [2]. These findings align with emerging evidence that subsets of glioneuronal tumors are driven by oncogenic receptor tyrosine kinase fusions and may exhibit distinct molecular profiles within this spectrum [10, 11]. Interestingly, similar CLIP2::MET fusions have been documented in rare pediatric cases, including spontaneous regression in congenital high-grade gliomas and low-grade glioneuronal tumors, suggesting diverse clinical implications [7, 9] (Table 1). While prior reports have described CLIP2::MET fusions in both high-grade and low-grade gliomas, our case further refines this spectrum by integrating multi-platform methylation profiling and demonstrating a lack of definitive class assignment despite consistent proximity to glioneuronal reference cohorts. Table 1Reported CNS tumors with CLIP2::MET fusionStudyAge/SexLocationHistology / gradeMethylation resultMolecular findingsTreatmentOutcomeCurrent case19/FRight frontal lobeLow-grade glioneuronal tumorNo match by classifier; reproducible proximity to the low-grade glioneuronal/ganglioglioma spectrumCLIP2::MET fusion (in-frame; MET exon 14 breakpoint; kinase domain retained); IDH1/2 and BRAF wildtype; no significant CNVs; MGMT unmethylatedGross total resectionNo recurrence at 6 monthsChapman et al. 2024 [7] – Case 14/MLeft occipital lobeLow-grade glioneuronal tumorNo match by classifier; clustered with low-grade glioma, hemispheric pilocytic astrocytoma/ganglioglioma subclassCLIP2 exon 11::MET exon 15; copy-number losses involving 1p, 6p, 6q, 7q, 9p, 19q, and 22qGross total resection; no adjuvant therapyDisease-free at 6 monthsChapman et al. 2024 [7] – Case 28/MRight parieto-occipital lobeLow-grade glioneuronal tumorNo match by classifier; clustered with low-grade glioma, dysembryoplastic neuroepithelial tumor subclassCLIP2 exon 11::MET exon 15; gain of 1q, 7q copy-number alterations, and loss of 22qNear-total resection; no adjuvant therapyStable residual disease at 3 yearsChowdhury et al. 2020 [8]30/FLeft parietal lobeGlioneuronal tumor with low-grade featuresClustered with low-grade glioma, specifically dysembryoplastic neuroepithelial tumor, on t-SNECLIP2 exon 12::MET exon 15; chromosome 1 and 7 abnormalities; MAPK-pathway upregulation describedGross total resection; no adjuvant therapyRemission / disease-free at 7 yearsRiedmeier et al. 2021 [9]Neonatal male (36-week preterm)Left frontal/temporal lobeCongenital high-grade gliomaClassified as infantile hemispheric gliomaCLIP2::MET fusion by next-generation sequencing; additional co-alterations not clearly detailedBiopsy onlySpontaneous regression; small stable residual tumor at 5 months Table 1Reported CNS tumors with CLIP2::MET fusionStudyAge/SexLocationHistology / gradeMethylation resultMolecular findingsTreatmentOutcomeCurrent case19/FRight frontal lobeLow-grade glioneuronal tumorNo match by classifier; reproducible proximity to the low-grade glioneuronal/ganglioglioma spectrumCLIP2::MET fusion (in-frame; MET exon 14 breakpoint; kinase domain retained); IDH1/2 and BRAF wildtype; no significant CNVs; MGMT unmethylatedGross total resectionNo recurrence at 6 monthsChapman et al. 2024 [7] – Case 14/MLeft occipital lobeLow-grade glioneuronal tumorNo match by classifier; clustered with low-grade glioma, hemispheric pilocytic astrocytoma/ganglioglioma subclassCLIP2 exon 11::MET exon 15; copy-number losses involving 1p, 6p, 6q, 7q, 9p, 19q, and 22qGross total resection; no adjuvant therapyDisease-free at 6 monthsChapman et al. 2024 [7] – Case 28/MRight parieto-occipital lobeLow-grade glioneuronal tumorNo match by classifier; clustered with low-grade glioma, dysembryoplastic neuroepithelial tumor subclassCLIP2 exon 11::MET exon 15; gain of 1q, 7q copy-number alterations, and loss of 22qNear-total resection; no adjuvant therapyStable residual disease at 3 yearsChowdhury et al. 2020 [8]30/FLeft parietal lobeGlioneuronal tumor with low-grade featuresClustered with low-grade glioma, specifically dysembryoplastic neuroepithelial tumor, on t-SNECLIP2 exon 12::MET exon 15; chromosome 1 and 7 abnormalities; MAPK-pathway upregulation describedGross total resection; no adjuvant therapyRemission / disease-free at 7 yearsRiedmeier et al. 2021 [9]Neonatal male (36-week preterm)Left frontal/temporal lobeCongenital high-grade gliomaClassified as infantile hemispheric gliomaCLIP2::MET fusion by next-generation sequencing; additional co-alterations not clearly detailedBiopsy onlySpontaneous regression; small stable residual tumor at 5 months Reported CNS tumors with CLIP2::MET fusion Different fusion partners may influence receptor dimerization, localization, and downstream signaling activity, as demonstrated by recent studies showing that the oncogenic behavior of MET fusions depends on their structural topology and fusion partner context [2, 15]. CLIP2 encodes a cytoskeleton-associated protein with CAP-Gly domains that mediate microtubule interactions, potentially affecting intracellular trafficking and MET signaling dynamics [16–18]. Comparatively, our patient’s tumor exhibited low-grade histological characteristics, including minimal mitotic activity, low Ki-67 labeling index, and absence of necrosis or microvascular proliferation, aligning with previously reported low-grade cases harboring similar molecular alterations [7, 8]. This divergence in clinical behavior despite shared genetic features may reflect differences in additional genetic, epigenetic, or environmental interactions. The clinical implications of specific MET fusion partners remain unclear, as reported cases demonstrate heterogeneous behavior ranging from indolent low-grade lesions to aggressive high-grade gliomas, and it is not yet established whether specific fusion partners confer distinct clinical trajectories. The differential diagnosis for this tumor includes several low-grade glioneuronal entities with overlapping histological and molecular features. Ganglioglioma is characterized by dysmorphic neurons and glial elements, often with CD34 expression and frequent BRAF alterations, which were not identified in this case. Dysembryoplastic neuroepithelial tumor typically demonstrates specific glioneuronal elements and FGFR1 alterations, which were not observed. Polymorphous low-grade neuroepithelial tumor of the young (PLNTY) often shows oligodendroglioma-like features with CD34 positivity and MAPK pathway alterations, while multinodular and vacuolating neuronal tumor (MVNT) is defined by characteristic vacuolated nodules and distinct imaging features, neither of which were present. Extraventricular neurocytoma may enter the differential given neuronal marker expression, but typically exhibits uniform round cells with perinuclear halos and lacks a prominent glial component. Angiocentric glioma is distinguished by perivascular growth patterns and MYB/MYBL1 alterations, which were not seen. In this context, the absence of canonical alterations (e.g., BRAF, FGFR1), combined with non-classifying methylation profiling and the presence of a CLIP2::MET fusion, supports classification within the glioneuronal tumor spectrum while highlighting its molecular distinction. Molecular characterization of our tumor revealed no other significant oncogenic alterations, further emphasizing the unique pathogenic role of the CLIP2::MET fusion in this context. Given the actionable nature of MET fusions, targeted therapies utilizing MET inhibitors such as crizotinib and tepotinib, which have demonstrated efficacy in MET-altered cancers and pediatric high-grade gliomas, may represent potential therapeutic options in recurrent or progressive cases [2]. The integration of molecular findings, clinical outcomes, and histopathological features suggests that CLIP2::MET-fused glioneuronal tumors could represent a distinct biological entity with variable clinical presentations. Further investigation into larger cohorts and comprehensive genomic profiling is essential to elucidate the clinical significance, optimal management strategies, and prognostic implications associated with this novel molecular subtype. This case expands the spectrum of CLIP2::MET fusion–positive CNS tumors and highlights the importance of recognizing MET-driven alterations in diagnostically challenging glioneuronal neoplasms. Further studies are needed to better define their clinical behavior, therapeutic relevance, and management strategies. As molecular characterization advances, MET fusion–positive glioneuronal tumors may represent a biologically meaningful subset within the broader glioneuronal tumor spectrum, warranting consideration in future classification frameworks.